Skip to main content
. 2013 Dec;57(12):5924–5930. doi: 10.1128/AAC.00656-13

Fig 2.

Fig 2

Dose-ranging study results for each of the four E. coli (A to D) and three K. pneumoniae (Kp) (E to G) clinical isolates. The effect of each active regimen relative to the no-treatment controls is shown. TOL, ceftolozane; TAZ, tazobactam. Error bars represent the range of data over two studies.